10 penny biotechs I'm watching and slowly adding for October/November 2026, and the one I got wrong in September.
CMPX is trading below cash with $180M cash against $147M market cap and 34 months of runway, providing downside protection. An ESMO oral presentation on Oct 24 and FDA feedback on a biliary-tract-cancer therapy create a near-term catalyst, though the recent SEC feedback has caused uncertainty.